Shares of Medigene AG (ETR:MDG1 – Get Free Report) were up 2.5% during mid-day trading on Wednesday . The company traded as high as €1.59 ($1.71) and last traded at €1.58 ($1.70). Approximately 6,863 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 306,207 shares. The stock had previously closed at €1.54 ($1.66).
Medigene Stock Performance
The firm has a market capitalization of $12.02 million, a price-to-earnings ratio of -2.66, a PEG ratio of 7.12 and a beta of 0.84. The stock has a fifty day moving average price of €1.58 and a 200-day moving average price of €1.57. The company has a current ratio of 2.39, a quick ratio of 5.85 and a debt-to-equity ratio of 12.95.
About Medigene
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.
See Also
- Five stocks we like better than Medigene
- What is the MACD Indicator and How to Use it in Your Trading
- Energy Transfer: Powering Data With Dividends and Diversification
- NYSE Stocks Give Investors a Variety of Quality OptionsÂ
- Qualcomm Stock Is Coiling for a Breakout
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Receive News & Ratings for Medigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigene and related companies with MarketBeat.com's FREE daily email newsletter.
